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Abstract
Recently, a previously unrecognized autoantibody mediated
blistering disease, paraneoplastic pemphigus has been de-
scribed. Paraneoplastic pemphigus is associated with lymphoid
malignancies, thymomas, and poorly differentiated sarcomas.
Serum of affected patients contain pathogenic autoantibodies
that immunoprecipitate from normal keratinocytes a character-
istic complex of four polypeptides with M, of 250, 230, 210,
and 190 kD. As our preliminary studies indicated that the 250-
kD and the 210-kD antigens comigrated with desmoplakins I
and II, we investigated the possibility that autoantibodies
against the desmoplakins were a component of this autoim-
mune syndrome. 11 sera from affected patients were tested by
indirect immunofluorescence against desmosome containing
tissues, immunoprecipitation of metabolically labeled keratino-
cytes, and Western immunoblotting of desmoplakins I and II
that had been purified to homogeneity from pig tongue epithe-
lium. By indirect immunofluorescence, 9 of 11 sera showed
strong binding to epithelial and nonepithelial desmosomes, and
2 were weakly reactive. All 11 immunoprecipitated 250- and
210-kD bands of variable intensity that comigrated with bands
identified by a murine monoclonal antidesmoplakin antibody,
and immunoblotting confirmed binding of the serum autoanti-
bodies to purified desmoplakins. This demonstrates that para-
neoplastic pemphigus is the first human autoimmune syndrome
in which autoantibodies against the desmoplakins are a promi-
nent component of the humoral autoimmune response. (J. Clin.
Invest. 1992. 89:1775-1782.) Key words: pemphigus * cell ad-
hesion * desmosomes - autoimmunity * paraneoplastic syn-
dromes
Introduction
Human autoantibodies in bullous skin diseases such as pem-
phigus and pemphigoid have been instrumental in the identifi-
cation ofimportant structural proteins ofthe skin and mucosa.
The use of these human reagents has provided much informa-
tion about cell adhesion molecules of stratified squamous epi-
thelia, desmosomal, and hemidesmosomal proteins (reviewed
in reference 1).
A preliminary report ofthis work has appeared in abstract form (1991.
Clin. Res. 39:195A).
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Paraneoplastic pemphigus (PNP)' is an autoimmune syn-
drome defined by the following criteria: (a) The presence of
mucosal erosions and a polymorphous skin eruption, with pa-
pular lesions eventually progressing to blistering and erosive
lesions affecting the trunk, extremities, and palms and soles in
the context of an occult or known neoplasm. (b) Cutaneous
histologic changes consisting of epidermal vacuolar interface
dermatitis, keratinocyte necrosis, and intraepidermal cell-cell
detachment (acantholysis). (c) The demonstration of IgG and
complement components on the affected epithelial cell sur-
faces, and often granular/linear complement deposition along
the basement membrane zone. (d) Serum autoantibodies that
bind to the cell surface of stratified squamous epithelia in a
pattern common to all forms of pemphigus, but unlike other
forms of pemphigus, these autoantibodies also bind to simple,
columnar, and transitional epithelia. (e) These serum autoanti-
bodies immunoprecipitate a complex of four high molecular
weight proteins from keratinocytes, with estimated mol wt of
250,000, 230,000, 210,000, and 190,000 (2). To date the neo-
plasms most commonly associated with paraneoplastic pem-
phigus are (in decreasing order of frequency) non-Hodgkin's
lymphomas, chronic lymphocytic leukemia, thymomas, and
poorly differentiated spindle cell sarcomas. The autoantibodies
from these patients are pathogenic by passive transfer into neo-
natal mice, where they induce acantholysis ofskin and esopha-
geal mucosa.
The desmoplakins (desmoplakin I and II) are two major
proteins located in the innermost portion of the desmosomal
plaque. Their sequence and structure are known (3, 4) and
desmoplakin II is apparently a product of alternate splicing of
the desmoplakin I transcript (5). Desmoplakin I has a M,
= 250,000 in SDS-PAGE and a calculated mol wt of 201,000.
Desmoplakin II has a Mr = 210,000 in SDS-PAGE. Until now,
no human autoantibodies against the desmoplakins had been
found. Our study illustrates that human autoantibodies against
the desmoplakins do indeed exist in paraneoplastic pemphigus
and are a specific marker for the syndrome; however, the role
of the antidesmoplakin antibodies in the pathogenesis of this
autoimmune syndrome remains speculative at present.
Methods
The diagnostic criteria for classification as PNP in this study included
the following criteria: an ulcerative and blistering mucocutaneous dis-
ease, associated with an underlying neoplasm, and autoantibodies
against the characteristic antigen complex previously described (2).
Serum was obtained from 11 patients with paraneoplastic pemphigus
as so defined. Of these patients, the associated neoplasms were as fol-
lows: non-Hodgkin's lymphoma, n = 5; chronic lymphocytic leuke-
mia, n = 2; poorly differentiated spindle cell sarcomas, n = 2; benign
thymoma, n = 1, and Castleman tumor (giant lymph node hyperplasia,
1. Abbreviations used in this paper: DP, desmoplakin; PV, pemphigus
vulgaris; PNP, paraneoplastic pemphigus.
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6), n = 1. Additional antibodies used in the study included a murine
monoclonal antibody specific for desmoplakins I and II (clone 2.15,
Boehringer-Mannheim Corp., Indianapolis, IN), and as secondary anti-
bodies where appropriate, a polyclonal rabbit anti-mouse IgG (Miles-
Yeda Ltd., Israel), an affinity-purified FITC goat anti-human IgG,
FITC goat anti-mouse IgG (Cappel Laboratories, West Chester, PA),
and phycoerythrin anti-mouse IgG (Phycoprobe; Biomeda, Foster
City, CA). Both the FITC anti-human IgG and the Phycoprobe were
tested by Ouchterlony double immunodiffusion against human and
mouse serum and by indirect immunofluorescence and were found to
lack any interspecies cross-reactivity.
Indirect immunofluorescence was performed on tissues derived
from BALB/c mice after cervical dislocation. The following tissues
were embedded in optimal cutting temperature medium (Tissue-Tek;
Miles Laboratories Inc., Elkhart, IN): esophagus, trachea, myocar-
dium, small and large bowel, gall bladder, urinary bladder, kidney, and
liver. Sections were first incubated with either dilutions of serum from
patients, control subjects, or the murine monoclonal antibody to des-
moplakin I and II followed by the addition of the appropriate second-
ary FITC anti-IgG. Slides were examined with a fluorescence micro-
scope (Olympus, Tokyo, Japan). Control sera for immunofluorescence
studies were obtained from patients with bullous pemphigoid, pemphi-
gus vulgaris, pemphigus foliaceus, and normal human serum.
Indirect immunofluorescence was also performed on keratinocyte
cultures using confocal microscopy. Keratinocytes were grown in
chamber slides (Lab-Tek; Nunc, Naperville, IL) in keratinocyte growth
medium (Clonetics Corp., San Diego, CA) to near confluence. They
were then incubated in Dulbecco's MEM with 10% FCS (both from
Sigma Chemical Co., St. Louis, MO) for 1 h at 370C, followed by
sequential incubation with a dilution of serum from patient 6 and the
monoclonal antidesmoplakin in the presence of 0.01% sodium azide
(Sigma) at 4°C for 1 h, followed by FITC anti-human IgG and phy-
coerythrin anti-mouse IgG, also at 4°C.
Immunoprecipitation was performed according to the technique of
Stanley et al. (7, 8). Human keratinocytes grown in keratinocyte
growth medium to near confluence were incubated with '4C-labeled
amino acids (New England Nuclear, Boston, MA) for 18 h. Cultures
were extracted in 0.5% NP-40 (Calbiochem Corp., La Jolla, CA) in
Tris-buffered saline with 2 mM PMSF (Sigma), centrifuged at 100,000
g for 1 h, and the supernatant was dialyzed against 0.3% NP-40 in
Tris-buffered saline. Labeled extracts were sequentially incubated with
normal human serum, protein A-bearing staphylococci (Pansorbin;
Calbiochem), test sera (from paraneoplastic patients, controls, or anti-
desmoplakin antibodies), and then staphylococcal protein G-agarose
(ImmuBind; Genex, Gaithersburg, MD). Immunoprecipitated pro-
teins were separated by SDS-PAGE, using a 5% slab gel, and the sepa-
rated proteins were visualized by autoradiography. Control sera for
immunoprecipitation were obtained from 15 patients with pemphigus
vulgaris, 10 patients with pemphigus foliaceus, 3 patients with coexis-
tent pemphigus vulgaris and adenocarcinomas ofthe bowel, 2 patients
with coexistent pemphigus foliaceus and neoplasia (squamous-cell car-
cinoma in 1 patient and benign thymoma in the other), 10 patients
with cicatricial pemphigoid, 15 with bullous pemphigoid, 2 with epi-
dermolysis bullosa acquisita, 6 with linear IgA dermatitis, 10 with sys-
temic lupus erythematosus with cutaneous involvement, 61 patients
with erythema multiforme, 1 with dermatomyositis and ovarian carci-
noma, 2 with cutaneous T-cell lymphoma, 2 with chronic myeloge-
nous leukemia and "a rash", and 6 healthy subjects.
Epidermal extracts used in Western immunoblots were prepared
from the skin of 1-2-d old BALB/c mice. After euthanasia, the epider-
mis was separated from the dermis by 40-s exposure to 0.02 M EDTA
(Sigma) in PBS at 560C. 1 g ofepidermis was minced and sequentially
homogenized in 5 ml each of 1% NP-40, 1 M NaCl, and 1% SDS
(Bio-Rad Laboratories, Richmond, CA) with 5% beta-mercaptoeth-
anol (Bio-Rad) using a motor-driven Teflon-type Potter-Elvejem ho-
mogenizer. 2 mM PMSF was added with each extraction, and the ho-
mogenate was centrifuged in a centrifuge (RC5B; Sorvall Instruments
Div., DuPont Co., Newton, CT) at 4VC and 15,000 rpm for 20 min.
Following the last extraction, 1 mM PMSF, 10mM EDTA, and 2 mM
microbial protease inhibitors (Bio-Rad; pepstatin/chymostatin in
DMSO, and antipain/leupeptin in water, 9) were added. The homoge-
nate was then boiled for 3 min, centrifuged, and the supernatant was
aliquoted and frozen at -70'C.
Purification of the desmoplakins used in Western blots was per-
formed according to the methods ofO'Keefe (10). Briefly, desmosomes
were isolated by extraction of pig tongue epithelium in sodium citrate
buffer with 0.05% NP-40 in the presence of proteinase inhibitors, de-
oxyribonuclease, and ribonuclease. Desmoplakin isolation included
extraction in 4 M urea, followed by alternating ion exchange chroma-
tography, gel filtration, and a second round ofion exchange chromatog-
raphy. Analysis for purity to homogeneity was established by comigra-
tion with desmoplakins extracted from desmosomes, isoelectric point
comparisons, peptide mapping and amino acid composition analysis,
and reaction ofthe purified polypeptides with monoclonal antibody to
desmoplakins.
All reagents used in Western blots were obtained from Sigma unless
otherwise specified. All electrophoresis reagents were obtained from
Bio-Rad Laboratories. SDS-PAGE in a borate-sulfate discontinuous
system was performed as described by Neville (11). The total acrylam-
ide concentration in the separation (lower) gel was 5%, and the ratio of
acrylamide to NN-methylenebisacrylamide was 40:1. High molecular
weight standards (50,000-210,000; Bio-Rad) were used for reference.
After separation by electrophoresis, proteins were transferred to
nitrocellulose (Millipore Corp., Bedford, MA) as described by Towbin
et al. ( 12). The nitrocellulose strips were incubated for 1 h with block-
ing solution (PTX; 150 mM NaCl, 10 mM NaPO4 pH = 7.5, 1 mM
EGTA, 0.2% Triton X, 0.006% NaAzide, 4% BSA), washed, and then
probed with either patient sera, control sera, or murine monoclonal
antibody to desmoplakins I and II. After further washes and blocking,
the strips were incubated with I251-staphylococcal protein A (NEN,
Boston, MA), and visualized by autoradiography.
Results
Sera from patients with pemphigus, paraneoplastic pemphigus,
and the monoclonal antidesmoplakin antibody all bound to
Figure 1. Fig. 1 demonstrates representative indirect immunofluorescence of four substrates, each substrate oriented horizontally by row: monkey
esophagus (A, B, C), murine small intestine (D, E, F), murine myocardium (G, H, I), and murine liver (J, K, L). Primary antibodies included
serum from a patient with pemphigus vulgaris (PV) as a "negative" control (vertically oriented by column, A, D, G, J), serum from a patient
with paraneoplastic pemphigus (PNP)-(B, E, H, K), and the murine monoclonal antidesmoplakin (anti-DP) as a positive control (C, F, I, L).
Secondary antibodies were FITC anti-human or FITC anti-murine IgG.
The cell surface of stratified squamous epithelium of monkey esophagus stained with PV sera (A), PNP sera (B), and anti-DP antibody (C).
PV autoantibodies failed to bind to all other tissues, including intestinal epithelium (D), myocardium (G), and liver (J). However, both the
PNP sera (E), and anti-DP antibody (F) show binding to the intestinal epithelium, with accentuation of binding in the subapical membrane
where desmosomes are most concentrated. Both the PNP sera and anti-DP monoclonal bound the intercalated discs of myocardium (H and I,
respectively), and both also bound punctate structures on the hepatocyte cell surface and along bile canaliculi (shown as parallel punctate rows
of dots, highlighted by the white arrows) that correspond precisely with the known distribution of desmosomes in liver. Bar = 20 zm.
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Figure 2. This demonstrates double-labeled indirect immunofluorescent confocal microscopy on keratinocyte cultures incubated with serum
from patient 6 (A) and the murine monoclonal anti-desmoplakin antibody (B). Secondary antibodies were FITC anti-human IgG and phycoer-
ythrin labeled anti-mouse IgG (both the anti-human and anti-mouse secondary antibodies showed no interspecies cross-reactivity). Both the
human serum and the monoclonal antidesmoplakin bound identical discrete dots at the cell periphery of the keratinocytes, corresponding to the
known distribution ofdesmosomes in keratinocyte cultures. (x-y axis, original magnification, 630; optical section 0.75-pm thickness).
the cell surface of the stratified squamous epithelium of mon-
key esophagus in a similar pattern. The paraneoplastic sera and
antidesmoplakin monoclonal did bind all layers of the epithe-
hum more diffusely than the pemphigus sera, but this differ-
ence was quite subtle. In contrast, a striking difference was seen
in the binding ofautoantibodies from paraneoplastic pemphi-
gus sera to simple epithelium ofgastrointestinal mucosa (small
intestine, colon, and gall bladder) and urinary bladder, as well
as nonepithelial tissues in which desmosomes are present
(myocardium, kidney, and liver). These tissues do not stain
with pemphigus vulgaris or foliaceus sera, but both the paran-
eoplastic pemphigus sera and antidesmoplakin antibody stain
these tissues in very similar patterns. Fig. 1 shows representa-
tive sections demonstrating binding of paraneoplastic sera to
esophageal mucosa, to the subapical membrane of intestinal
epithelia (where belt desmosomes are concentrated [ 13]), to the
intercalated discs of myocardium, and focal structures on the
hepatocyte cell surface and along bile canaliculi (corresponding
to desmosomes stained by the monoclonal antibody). Ofthe 11
paraneoplastic pemphigus sera tested, 9 had unequivocal stain-
ing in the pattern described. Two had weaker reactivity with
nonstratified squamous epithelia and could not be distin-
guished with complete certainty by these immunofluorescent
criteria alone.
Fig. 2 shows double labeling on human keratinocytes in
culture, using sera from a patient with paraneoplastic pemphi-
gus and the murine monoclonal antidesmoplakin, viewed by
confocal microscopy. Fig. 2A is labeled with an FITC anti-hu-
man IgG and Fig. 2 B is labeled with a phycoerythrin anti-
murine IgG. One can see identical binding of both antibodies
to discrete dots, corresponding to the distribution of the des-
mosomes at the periphery of the cultured cells. This distribu-
tion ofbinding ofantidesmoplakin antibodies to cultured kera-
tinocytes is identical to that reported by Ma et al. (14).
Fig. 3, A and B, shows the complex and characteristic anti-
gen bands that are immunoprecipitated by sera ofpatients with
paraneoplastic pemphigus. With the exception of the 230-kD
bullous pemphigoid antigen, none of these bands were immu-
noprecipitated by the control sera from other diseases, includ-
ing those patients with typical pemphigus vulgaris or pemphi-
gus foliaceus. Heavily labeled 250- and 210-kD bands were
precipitated by 9 of the 11 paraneoplastic pemphigus patients'
sera, but not with any of the control sera. With two sera, these
bands were only faintly visualized, and these were the same
sera that reacted weakly with nonepithelial desmosomes by
indirect immunofluorescence. The antidesmoplakin antibody
immunoprecipitated bands that comigrated precisely with the
250-kD band identified by these sera. The 210-kD desmopla-
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Figure 3. Figure 3, A and B, demonstrates immunoprecipitation of
metabolically labeled keratinocyte cultures by the sera ofindividual
patients with paraneoplastic pemphigus. The numbers at the bottom
of each lane correspond to the assigned patient case number. The
controls include immunoprecipitates from the same extract produced
by incubation with sera from patients with bullous pemphigoid (BP),
from pemphigus vulgaris (PV), and a murine monoclonal antides-
moplakin antibody (aDP). Desmoplakin I and II bands are both
marked by solid arrowheads. A band that comigrates precisely with
desmoplakin I is clearly visualized by the monoclonal antibody and
with variable intensity by sera from all patients with paraneoplastic
pemphigus. Desmoplakin II is seen as a faint band that migrates just
above the 200-kD myosin marker, consistent with its migration in
SDS-PAGE at - 210 kD. This band is more heavily labeled by the
patients' sera than the monoclonal for reasons that are not clear. The
band recognized by the antidesmoplakin that migrates immediately
below the myosin marker (asterisk) is only very faintly recognized by
the patients' sera, and its identity is not clear. The band labeled by
the shadowed arrowhead appears to be a degradation product of the
purified desmoplakin II, as it is variably detected both by patients'
sera and in the purified protein solution ofDP II in immunoblotting.
Finally, the identity of the lower molecular weight antigen bands
(identified by the open arrows) that do not react with the antidesmo-
plakin antibody is currently unknown. Cis a Western immunoblot
of purified desmoplakin I and 11 (I and II at the top of each lane)
probed with PNP patients' sera (labeled by the case number) and the
monoclonal antibody against desmoplakin I and II (aDP). All sera
kin II is recognized as a faint discrete band with the monoclo-
nal antibody, and as a much more heavily labeled band by the
paraneoplastic patients' sera. The monoclonal anti-DP I and II
monoclonal also recognizes a heavily labeled band that mi-
grates just below the myosin molecular weight marker. It is not
clear what this band represents, for it does not bind the mono-
clonal in the Western immunoblots (Fig. 3 C) and it is also not
precipitated by the patients' sera. There is also an apparent
* degredation product of the desmoplakin II polypeptide that is
detected by both the patients' sera and in the Western immun-
oblots that migrates immediately below this band. The lower
molecular weight bands that are apparent in the immunopreci-
pitates at 170 kD and 90 kD remain unidentified at present but
are obvious in most samples. These bands were not visualized
as clearly in the original description ofthis syndrome, and their
importance is currently being investigated. The 230-kD bul-
lous pemphigoid antigen is detected by the control bullous
pemphigoid serum used, and comigrating bands are obviously
precipitated by only four of the eleven paraneoplastic pemphi-
W gus patients' sera.
The 1 30-kD pemphigus vulgaris antigen is not visualized in
these photographs, because of the extended autoradiographic
exposure required to visualize this protein. The complex iden-
tified by paraneoplastic pemphigus sera is readily visualized
after one week ofexposure, but the pemphigus vulgaris antigen
requires approximately three weeks ofautoradiography for vi-
sualization. When this lengthy exposure was performed, the
expected pemphigus antigen bands were seen with the control
pemphigus sera, but no comigrating antigen bands were de-
tected in the antigen complex identified by the paraneoplastic
pemphigus sera (data not shown).
Western immunoblot analysis was performed with polypep-
tides extracted from neonatal murine epidermis probed with
sera from 11 paraneoplastic pemphigus patients, and controls:
one pemphigus vulgaris patient, two pemphigus foliaceus pa-
tients, one bullous pemphigoid patient, and three normal sub-
jects. The antidesmoplakin antibody identified bands that co-
migrated precisely with the antigens at 250 and 210 kD. Fig. 3
Cshows Western immunoblotting with purified desmoplakin I
and desmoplakin II in adjacent lanes, employing the patients'
sera that had the most consistent reactivity in immunoblotting
with whole murine epidermal extracts. Both purified desmo-
plakin I and desmoplakin II was bound by autoantibodies pres-
ent in a total of 7 of the 11 PNP patients' sera. The patients'
sera recognized the desmoplakin II band that migrated just
above the myosin molecular weight marker, and the presumed
degradation product ofDP II described previously. Binding to
the immobilized desmoplakins was more variable than that
stain both desmoplakins I and II. Desmoplakin II migrates just above
the myosin marker, corresponding with the fine band identified by
the same antibody in immunoprecipitation (Fig. 3, A and B, solid ar-
rowhead). There is also an apparent degradation product of desmo-
plakin II that is identified both in the immunoblots and by precipita-
tion (Fig. 3, A and B, shadowed arrowhead). The heavily labeled band
immediately below the 2 lO-kD desmoplakin II band seen in the im-
munoprecipitates (asterisk) is not recognized in Western immuno-
blots. These final data confirm that PNP autoantibodies are specifi-
cally directed against the desmoplakins and are not nonimmunologi-
cally coprecipitated.
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demonstrated with the nondenatured polypeptides by immu-
noprecipitation.
Discussion
In this paper we have established that patients with the newly
described syndrome, paraneoplastic pemphigus, mount a com-
plex immune response which includes autoantibodies directed
specifically against desmoplakins I and II. This specific affinity
is suggested by indirect immunofluorescence studies that dem-
onstrate binding to epithelial and nonepithelial desmosomes,
by immunoprecipitation of high molecular weight antigens
that comigrate with the desmoplakins, and is confirmed by
binding of the antibodies to purified desmoplakin I and II by
Western immunoblotting. The reactivity of patients' autoanti-
bodies by immunoblotting establishes another important
point, that the desmoplakins are not simply coprecipitated, but
are targets of the autoantibodies. This is worth stressing, for in
both pemphigus vulgaris and pemphigus foliaceus, a desmoso-
mal plaque protein, plakoglobin (15) is nonimmunologically
coprecipitated in immunoprecipitation techniques due to the
presence of both reducible and nonreducible cross-linking to
the pemphigus vulgaris and foliaceus antigens (16). Both the
indirect immunofluorescent binding and the immunoblotting
studies presented herein establish that this is not the case in
paraneoplastic pemphigus, and the patients' autoantibodies
are, in fact, directed against epitopes present on the desmoso-
mal plaque proteins, desmoplakins I and II.
The reaction of patients' antibodies with the desmoplakins
is not completely constant, and varies amongst individual pa-
tients' sera. As one might expect, we found that those patients'
sera that react most strongly by immunofluorescence and im-
munoprecipitation also react most consistently by immuno-
blotting with purified desmoplakins. The most sensitive test for
the presence ofthese autoantibodies appears to be immunopre-
cipitation of metabolically labeled keratinocytes. Unequivocal
detection ofthe characteristic autoantibodies in paraneoplastic
pemphigus by immunofluorescent criteria alone was possible
in only 9 of the 11 patients in this study. As reported in our
original description ofthe syndrome, in all cases we have tested
to date, the autoantibodies were polyclonal and predominantly
of the IgG 1 subclass (2).
The desmoplakins are major cytoskeletal structural pro-
teins that have been localized to the innermost portion of the
desmosomal plaque (reviewed in reference 17). Desmoplakin I
has been found in all desmosomes studied (13, 18), whereas DP
II has been found predominantly, but not exclusively, in strati-
fied squamous epithelia (19). Overlapping cDNA clones en-
coding two major domains of the human desmoplakins have
been identified (4), and suggest that DP I and II are encoded by
separate mRNAs derived from a single gene (5). Analysis of
these clones indicates that the central domain ofDP I contains
the heptad repeat characteristic ofmany a fibrous proteins and
forms a coiled coil dimer of 130 nm in length. The carboxy
terminus contains three regions each ofwhich includes almost
five repeats ofa 38-residue motif. These regions are thought to
assume globular conformations stabilized by intrachain ionic
interactions, and have been found to have significant homol-
ogy with regions of the 230-kD bullous pemphigoid antigen.
It is thought that desmoplakins may play a role in the at-
tachment ofintermediate filaments to the cell surface at the site
of the desmosome, but direct proof of this is lacking (3). The
periodicity in acidic and basic residues of the repeating car-
boxy-terminal domains in the desmoplakins is the same as the
found in that lB rod domain ofintermediate filament proteins.
Some have speculated that the desmoplakins could thus inter-
act directly with intermediate filaments, while others postulate
an as yet unidentified molecule that may mediate this interac-
tion.
Although we have previously reported that passive transfer
of whole immunoglobulin fractions from patients with para-
neoplastic pemphigus into neonatal mice can induce cutane-
ous and esophageal acantholysis (cell-cell detachment, 1, 2),
the role of the autoantibodies that are directed specifically
against the desmoplakins in the induction of lesions is not
known. Any speculation that they might be causative is tem-
pered by the fact that the desmoplakins are intracellular pro-
teins with no transmembrane or extracellular domains, and it
is not clear how serum autoantibodies could bind to and pre-
sumably compromise the function of such intracellular anti-
gens. It should also be noted that we transfused only autoanti-
bodies, and any cell-mediated autoimmune tissue injury would
not be reproduced in our passive transfer model.
Despite this, there are two striking "biological precedents"
ofparaneoplastic syndromes that are relevant to paraneoplastic
pemphigus, paraneoplastic cerebellar degeneration (20), and
loss of visual acuity, cancer-associated retinopathy (21, 22). In
paraneoplastic cerebellar degeneration, associated neoplasms
include ovarian carcinoma (most common, 23), Hodgkin's dis-
ease (24), ductal carcinoma of the breast (25), non-Hodgkin's
lymphoma (26), and mesodermal ovarian sarcoma (27). Auto-
antibodies found in the patients' sera react with 34 kD- and
62-kD antigens extractable from Purkinje cells (designated
CDR34 and CDR62 [28]; CDR, cerebellar degeneration re-
lated-antigen). CDR34 is evidently a cytoplasmic antigen of
the endoplasmic reticulum of neuroectodermal tissue (29) and
it is anomalously expressed only by the ovarian carcinoma cells
from patients with the paraneoplastic cerebellar degeneration
and is not present in similar tumors from unaffected subjects
(30). Cancer-associated retinopathy is usually associated with
small cell carcinoma of the lung (21) and autoantibodies that
bind antigens found within the nuclei of cells of the retinal
pigment epithelium, the choroid, and choroidal vessels (31,
32). Passive transfer ofhuman autoantibodies into rodents pro-
duces vesicular degradation of optic nerve myelin sheaths (32)
and reduction of retinal ganglion cells (33) in vivo. Unlike the
cerebellar degeneration syndrome, however, these autoanti-
gens can be extracted both from tumor of both affected and
unaffected individuals and from the human small cell lung
carcinoma cell line 119 (32, 34).
It is proposed that an "autoimmune" paraneoplastic syn-
drome results in part from the immunologic response of the
host to the tumor. According to this hypothesis, the host pro-
duces antitumor antibodies that react with the tumor and may
limit its growth. The antibodies may also gain access to and
cross-react with antigens on the specific target tissue and com-
promise its function. For this argument to be persuasive, it
must be shown that the patient produces antibodies that react
with tumor cells, that these antibodies bind in vivo to compo-
nents of normal host tissue, and compromise the physiologic
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function of that organ. These three conditions have been met
for paraneoplastic cerebellar dysfunction and cancer-asso-
ciated retinopathy, but only two of these criteria have been
established in the case of paraneoplastic pemphigus.
We do not know if autoantibodies in these patients' sera
react with tumor antigens from affected individuals. This line
of investigation has been hampered by the lack oftumor tissue
available for study, as this is a newly recognized syndrome and
most cases were recognized retrospectively after the death of
the affected individual. It is known that desmoplakins are ex-
pressed in thymomas and Castleman tumors, and it is likely
that the patients' autoantibodies will react with these tumors.
What is curious is that the majority of affected patients have
lymphomas or chronic leukemias of B cell origin, and it is
generally accepted that these cells do not produce desmosomes
or express desmoplakins.
However, the hypothesis that there may be a link between
the immune response against lymphoid neoplasms and desmo-
somal proteins finds some basis in a review of the literature. It
has been reported that, paradoxically, primitive tumors may
produce junctions that are not normally present in the tissue
from which the tumor originated. Desmosomes and "desmo-
some-like" cell junctions have been known to be anomalously
produced by tumors that do not normally posses desmosomes.
The list oftumors that are known to possess these desmosome-
like structures (by morphologic criteria) includes sarcomas,
lymphomas, neuroblastomas, and meningiomas (35, 36, 37).
In addition, the desmoplakins have been detected by immuno-
staining in reactive lymph nodes, tonsils, non-Hodgkin's B cell
lymphomas, and synovial sarcomas (38). These data provide
some basis for our speculation that these tumors may anoma-
lously produce antigens that are cross-reactive with epithelial
antigens, and the autoantibodies directed against tumor anti-
gen cause the mucocutaneous disease, but direct proof is lack-
ing. Arguing against this hypothesis is the notable absence of
paraneoplastic pemphigus in patients affected with much more
common tumors that also express desmoplakins and other epi-
thelial antigens such as squamous cell and basal cell carci-
nomas. Therefore, a more complex and as yet unexplored in-
teraction between these lymphoid tumors and the host may be
necessary to induce this rare phenomenon.
In conclusion, patients with paraneoplastic pemphigus pro-
duce antibodies, specifically desmoplakins I and II. The role of
these antibodies in the pathogenesis of tissue damage in the
syndrome is not yet known, and their role as a component of
the antitumor immune response remains to be investigated.
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